uniQure 10-Q: $768.4M Cash to 2030, Q3 Loss $61.2M, May 1 2027 PDUFA
QURE has more than doubled off its 52-week low of $8.73.
Summary
uniQure's Q3 10-Q shows a $61.2M net loss and $768.4M in cash funding operations into 2030, alongside a May 1, 2027 PDUFA date and a new risk factor flagging that the 48-month data missed its primary endpoint and was not in the BLA.
Key Events · Earnings and Guidance · QURE
-
Q3 Loss Narrows, Revenue Rises
Net loss was $61.2 million, or $0.88 per share, versus $80.5 million, or $1.38 per share, a year earlier. Total revenues rose to $5.2 million from $3.7 million on higher HEMGENIX royalties.
-
Cash of $768.4M Funds Operations Into 2030
Cash, cash equivalents and investment securities totaled $768.4 million at September 30, 2026, up from $622.5 million at December 31, 2025, which management says funds projected operating expenses into 2030 including launch preparation and the confirmatory study.
-
May 1, 2027 PDUFA; AdComm Tentatively Planned
The FDA accepted the AMT-130 BLA under Accelerated Approval with Priority Review and a May 1, 2027 target action date, and stated it is tentatively planning to convene an advisory committee. The MHRA validated the UK MAA in Q3 2026.
-
48-Month Primary Endpoint Missed Significance
At 48 months, cUHDRS showed 44% slowing of progression but did not reach statistical significance (p=0.144); TFC showed 61% slowing (p=0.008). A new risk factor states the 48-month topline results were not part of the BLA or MAA.
Analysis · QURE · Life Sciences
The full Q3 report confirms the company is funded well past the AMT-130 decision: $768.4M in cash and investments at September 30, 2026 versus $622.5M at year-end 2025, with management projecting runway into 2030. That matters because the FDA accepted the BLA under Priority Review with a May 1, 2027 PDUFA date and is tentatively planning an advisory committee, so the company can fund both the launch build-out and the ~200-patient confirmatory study without another raise. The offset is the data: the 48-month cUHDRS endpoint missed statistical significance (44% slowing, p=0.144), and the filing's new risk factor concedes the 48-month results were not part of the BLA or MAA — the agency may weigh them. A securities class action over the same Phase I/II disclosures is also live, with the motion to dismiss due today.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QURE was trading at $22.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $8.73 to $51.72. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.